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ABSTRACT 27 
 28 
Infection of ruminants and humans with Fasciola gigantica is attracting increasing attention 29 
due to its economic impact and public health significance. However, little is known of innate 30 
immune responses during F. gigantica infection. Here, we investigated the expression profiles 31 
of genes involved in Toll-like receptors (TLRs) and NOD-like receptors (NLRs) signaling 32 
pathways in buffaloes infected with 500 F. gigantica metacercariae. Serum, liver and peripheral 33 
blood mononuclear cell (PBMC) samples were collected from infected and control buffaloes at 34 
3, 10, 28, and 70 days post infection (dpi). Then, the levels of 12 cytokines in serum samples 35 
were evaluated by ELISA. Also, the levels of expression of 42 genes, related to TLRs and NLRs 36 
signaling, in liver and PBMCs were determined using custom RT2 Profiler PCR Arrays. At 3 37 
dpi, modest activation of TLR4 and TLR8 and the adaptor protein (TICAM1) was detected. At 38 
10 dpi, NF-κB1 and Interferon Regulatory Factor signaling pathways were upregulated along 39 
with activation of TLR1, TLR2, TLR6, TLR10, TRAF6, IRF3, TBK1, CASP1, CD80, and 40 
IFNA1 in the liver, and inflammatory response with activated TLR4, TLR9, TICAM1, NF-41 
κB1, NLRP3, CD86, IL-1B, IL-6, and IL-8 in PBMCs. At 28 dpi, there was increase in the 42 
levels of cytokines along with induction of NLRP1 and NLRP3 inflammasomes-dependent 43 
immune responses in the liver and PBMCs. At 70 dpi, F. gigantica activated TLRs and NLRs, 44 
and their downstream interacting molecules. The activation of TLR7/9 signaling (perhaps due 45 
to increased B-cell maturation and activation) and upregulation of NLRP3 gene were also 46 
detected. These findings indicate that F. gigantica alters the expression of TLRs and NLRs 47 
genes to evade host immune defenses. Elucidation of the roles of the downstream effectors 48 
interacting with these genes may aid in the development of new interventions to control disease 49 
caused by F. gigantica infection. 50 
 51 
Keywords: Fasciola gigantica; Gene expression; Host-pathogen interaction; Pattern 52 
recognition receptors; Toll-like receptors  53 
 54 
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1.   Introduction 55 
 56 
Fasciolosis is a parasitic disease caused by Fasciola gigantica and F. hepatica in tropical 57 
and temperate countries, respectively. These liver flukes can cause significant economic losses 58 
when they affect economically important livestock species (Spithill et al., 1999). Infection with 59 
Fasciola can adversely affect the liver and cause significant reduction in the productivity, 60 
growth rate and even death of the affected animal (Keiser and Utzinger, 2009; Molina et al., 61 
2006). Control of liver fluke infection has been challenging due to the lack of vaccines and 62 
increasing rate of drug resistance (Fairweather and Boray, 1999). These parasites are also 63 
common zoonotic agents (Keiser and Utzinger, 2007). Adult liver flukes have been recovered 64 
from the bile duct of humans (Inoue et al., 2007; Kanoksil et al., 2006; Sharifiyazdi et al., 2011). 65 
Also, infection has been linked to liver cirrhosis, fibrosis and cancer (Machicado et al., 2016), 66 
particularly in China, Korea, Africa, South America (Chen et al., 2013; Hotez et al., 2008). 67 
Despite the economic and public health importance of F. gigantica infection, its 68 
immunopathogenesis remains unclear.  69 
The outcome of Fasciola-host interaction depends on the ability of the host immune 70 
system to limit parasite replication and the ability of the parasite to evade or suppress the host 71 
immune defenses in order to promote its own survival in the host (Girones et al., 2007; 72 
Rodriguez et al., 2015; Zhang et al., 2017b). Fasciola spp. are very efficient in modulating the 73 
host immune response (Girones et al., 2007). While F. hepatica infection elicits a dominant 74 
Th2/T-regulatory immune response in sheep (Fu et al., 2016), F. gigantica infection induces a 75 
mix of Th1/Th2 response with a Th2-biased pattern in mice, cattle and buffaloes (Chantree et 76 
al., 2013; Molina, 2005). Recent studies have revealed transcriptomic changes associated with 77 
host’s immune response and metabolism in peripheral blood mononuclear cells (PBMCs) 78 
(Alvarez Rojas et al., 2015; 2016; Hacariz et al., 2015) and liver (Zhang et al., 2017b) in 79 
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response to Fasciola infection. Despite ongoing research on F. gigantica pathogenesis, little is 80 
known regarding the patterns of the host innate immune response to infection with F. gigantica. 81 
A better understanding of the immunoregulatory strategies employed by this parasite may guide 82 
the development of novel preventative and therapeutic interventions. 83 
Innate pattern-recognition receptors (PRRs), such as the membrane-associated Toll-like 84 
receptors (TLRs), cytosolic nucleotide-binding oligomerization domain (NOD)-like receptors 85 
(NLRs), RIG-I-like receptors (RLRs), C-type lectin receptors (CLRs), AIM2-like receptors 86 
(ALRs), and sequestosome 1/p62-like receptors (SLRs), are the first line of defense against 87 
microbial infections. These innate immune sensors can recognize pathogens, recruit innate 88 
immune cells and evoke adaptive immune responses (Cooney et al., 2010; Fukata et al., 89 
2009). The interaction between F. hepatica and host TLRs, and interference with subsequent 90 
downstream host signaling has been suggested (Flynn and Mulcahy, 2008). This interaction is 91 
greatly influenced by the fluke's excretory-secretory products (ESP), which could affect the 92 
regulation of various TLR signaling pathways. For example, fatty acid binding protein (FABP) 93 
of F. hepatica can suppress the inflammatory immune response via targeting multiple TLR 94 
pathways (Ruiz-Jiménez and Espino, 2014). FABP of F. hepatica (Fh12) was shown to inhibit 95 
TLR4 activation and suppress the inflammatory cytokines (Martin et al., 2015). F. 96 
hepatica ESP was also shown to affect MyD88-dependent signaling pathway (Falcon et al., 97 
2010). Ravidà et al., (2016) reported a role for CLRs in F. hepatica tegumental coat (FhTegs) 98 
interaction with bone marrow derived dendritic cells (DCs). Recently, mucin-derived peptide 99 
from F. hepatica (Fhmuc) was shown to enhance the stimulatory capacity of DCs and boost 100 
their ability to polarize T cell responses toward Th1 profiles, as well as increase the expression 101 
of TLR4 (Noya et al., 2017).  102 
While several studies have investigated levels of host cytokines induced by F. gigantica 103 
infection (Chantree et al., 2013; Molina, 2005; Zhang et al., 2017a), PRRs involved in the 104 
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signaling pathways governing host immune responses remain unknown. Given the ability of F. 105 
gigantica flukes to subvert host immune defenses, persist within the host and cause chronic 106 
liver disease, deciphering the roles of innate immune receptors that mediate recognition of F. 107 
gigantica is key to understanding the immunological basis that may lead to the clearance of this 108 
parasite from host tissues. Therefore, in this study we used commercial quantitative RT2 Profiler 109 
PCR Arrays to study the differential expression of 42 genes related to TLR- and NLR-mediated 110 
signal transduction and innate immunity in the liver and peripheral blood mononuclear cell 111 
(PBMCs) of buffaloes infected with F. gigantica. The levels of gene expression were 112 
determined in the liver and PBMC samples in order to capture a more comprehensive picture 113 
of the local and systemic immune responses against F. gigantica infection. In parallel to gene 114 
expression analysis, the levels of 12 serum cytokines were assessed using ELISA. 115 
 116 
2.   Materials and methods 117 
 118 
2.1. Ethics Statement 119 
 120 
The study was approved by The Animal Administration and Ethics Committee of Lanzhou 121 
Veterinary Research Institute, Chinese Academy of Agricultural Sciences. All animals were 122 
handled in strict accordance with good animal practice according to the Animal Ethics 123 
Procedures and Guidelines of the People's Republic of China. 124 
 125 
2.2. Metacercariae 126 
 127 
Eggs of F. gigantica were collected from the gall bladders of naturally infected buffaloes 128 
killed at local abattoirs in Guangxi Zhuang Autonomous Region, China, as previously described 129 
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(Zhang et al., 2017b). The collected eggs were incubated at 29 ºC for 11 days. The newly 130 
hatched miracidia were used to infect Galba pervia snails (3-5 miracidia/snail) maintained in a 131 
plastic culture plate for 2 hours. Then, infected snails were incubated in order to allow miracidia 132 
to develop to sporocysts, rediae and cercariae. After ~6 weeks fully-developed cercariae were 133 
shed from the snails and were harvested on 5×5 cm cellophane sheets and encysted into 134 
metacercariae.  135 
 136 
2.3. Animals and experimental infection 137 
 138 
Twenty-four (8-10-month-old) buffaloes were purchased from a water buffalo's farm in 139 
Guangxi Zhuang Autonomous Region, PR China. Animals were randomly divided into two 140 
groups: (i) 12 uninfected, control group and (ii) 12 infected group. Each group was further 141 
subdivided into 4 subgroups. Each subgroup of three buffaloes (infected or control) was 142 
examined at 3, 10, 28, and 70 days post infection (dpi) in order to assess the temporal alterations 143 
in the levels of serum cytokines and gene expression in liver and PBMC following F. gigantica 144 
infection. To rule out the possibility of any prior infection, fecal samples were examined 145 
microscopically for Fasciola eggs and sera were tested for anti-F. gigantica IgG and IgM 146 
antibodies using ELISA, as described previously (Chauvin et al., 1995; Zhang et al., 2017b). 147 
After acclimatization for 2 weeks, each buffalo was orally treated with a single dose of 148 
triclabendazole (Change Zhou Jialing Medicine Industry Co., Ltd., China) at a dose rate of 50 149 
mg/kilogram of body weight in order to ensure liver fluke-free status of the buffaloes used in 150 
this study. Following a withdrawal time of four weeks, metacercariae encysted on cellophane 151 
sheets were washed several times with sterile phosphate buffered saline (PBS) and used 152 
immediately to infect 12 buffaloes (500 metacercariae/animal), as previously described (Molina 153 
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and Skerratt, 2005; Phalee et al., 2015). Control buffaloes were mock-inoculated with 0.85% 154 
NaCl solution without metacercariae.  155 
 156 
2.4. Collection of liver and blood samples  157 
 158 
For each time point, 3, 10, 28, and 70 dpi, three animals from each of the infected and 159 
control groups were sacrificed and their livers were quickly collected. Liver samples were 160 
washed in PBS, cut into small pieces, immediately frozen in liquid nitrogen, and kept in small 161 
tubes at –80 °C until analysis. Frozen liver samples homogenization was obtained using a 162 
TissueLyser LT (Qiagen, Germantown, MD). Venous blood samples were collected and were 163 
allowed to clot at ambient temperature for 30 min, followed by centrifugation at 1,700 ×g for 164 
10 min at 20 °C. The serum layer was collected, divided into aliquots and frozen at –20 °C until 165 
use. Also, parallel blood samples were collected in 2-mL ethylenediaminetetraacetic acid 166 
(EDTA)-treated sterile tubes, and PBMCs were separated within 2 h after collection using the 167 
method described below.  168 
 169 
2.5. Cytokine determination 170 
 171 
The levels of 12 cytokines, namely tumor necrosis factor-α (TNF-α), transforming growth 172 
factor-β (TGF-β), interferon gamma (IFN-γ), interleukin-1β (IL-1β), IL-2, IL-4, IL-5, IL-6, IL-173 
12, IL-13, IL-17, and IL-18, in the buffalo's serum were determined using ELISA (Bovine 174 
cytokine ELISA kit, Blue Gene Biotech Inc., Shanghai, China) following the manufacturer's 175 
instructions. Frozen serum samples were thawed immediately before the analysis. The assay 176 
procedure was similar for all cytokines. Briefly, 100 µl of standard or serum sample were added 177 
into each well in the antibody pre-coated microtiter plate. Also, 100 µl PBS were added to three 178 
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blank wells to control for any variation or contribution, of the plate itself to the measured optical 179 
density (OD). Then, 50 µl of enzyme conjugate were added into each well, mixed thoroughly 180 
and incubated for 1 hr at 37 °C. Then, the mixture was removed and all wells of the microtiter 181 
plate were washed 5X with PBS. For color development, 50 µl of each of Substrate A and 182 
Substrate B were added to each well including blank wells, followed by 10 min incubation at 183 
37 °C in the dark. Finally, 50 µl of stop solution were added to each well and mixed with gentle 184 
tapping to terminate the reaction. OD of 450 nm (OD450) minus the background of plate 185 
absorbance was read on an ELISA microplate reader (BIO-RAD, Model 680). Even though the 186 
bovine cytokine ELISA kit has not been validated for use in buffaloes, the measured cytokines 187 
were within the detectable range of the kit. 188 
 189 
2.6. Isolation of PBMCs 190 
 191 
We used lymphocyte isolation kit (TBD Biological Technology Co., Tianjin, China) to 192 
obtain a suspension of PBMCs. Briefly, five ml diluent were added to 5 ml whole blood in a 193 
clean 10 ml glass centrifuge tube, followed by inversion of the tube several times to achieve 194 
good mixing. Then, 5 ml of the diluted blood was carefully overlaid over 5 ml lymphocyte 195 
separation medium without mixing of the two layers. Following centrifugation at 400 ×g for 30 196 
min at ambient temperature, the layer containing the mononuclear cells was harvested carefully 197 
into a fresh tube and was mixed with 10 ml PBS. Following centrifugation at 250 ×g for 10 min 198 
at ambient temperature, supernatant was removed and cell pellet containing the isolated PBMCs 199 
(approximately 5×106 cells) was resuspended in 1 ml RNAlater and stored at –80 °C until 200 
analysis.	  201 
 202 
2.7. RNA isolation and qRT-PCR 203 
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 204 
Total RNA was isolated from homogenized liver and purified PBMC samples by RNeasy 205 
Mini Kit (Qiagen Gmbh, Hilden, Germany). The RNA samples were treated with 10 µl RNase-206 
Free DNase to remove residual genomic DNA. The RNA quantity and purity was determined 207 
using NanoPhotometer® spectrophotometer at 260 nm/280 nm (Implen, CA, USA). Only RNA 208 
without DNA contamination and degradation of 26S rRNA was used for subsequent cDNA 209 
synthesis. One microgram of purified total RNA was used as a template to synthesize cDNA 210 
using First Strand cDNA Synthesis Kit according to the instructions of the manufacturer 211 
(Qiagen, Maryland, USA). The cDNA samples from liver and PBMCs were used as a template 212 
to quantify the expression level of 42 genes involved in TLR and NLR signaling pathways. 213 
Specifically, we examined genes related to TLRs (e.g. TLR1, TLR2, TLR3, TLR4, TLR5, 214 
TLR6, TLR7, TLR8, TLR9, TLR10), pathogen-specific responses (e.g. TICAM1, TBK1), TLR 215 
signaling (e.g. TRAF3, TRAF6, MYD88), signaling downstream of TLRs (e.g. [NFκB 216 
signaling: NFKB1], [Interferon Regulatory Factor (IRF) signaling: IFNG, IFNA1], [cytokine 217 
signaling: IL4, IL6, IL8, IL17A, IL18, IL13]), regulation of adaptive immunity (e.g. IL1B, 218 
IL12A, IL10), TLR interacting proteins and adaptors (e.g. RIPK2), and downstream effectors 219 
of TLR signaling (e.g. IRF3, IRF7). A list of all 42 gene targets investigated in the expression 220 
profiling analysis is provided (Table S1). 221 
Commercial quantitative real-time PCR (qRT-PCR) primers used in the present study were 222 
provided by Qiagen Custom RT2 Profiler PCR Array service. Quantitative mRNA 223 
measurements were performed with the RT2 SYBR® Green ROX qPCR Mastermix in ABI 224 
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7500 real-time PCR cycler. The amplification program was performed using the following 225 
cycling conditions: initial denaturation for 10 min at 95 ºC, followed by 40 cycles of 95 ºC for 226 
15 s and 60 ºC for 1 min. The data were normalized to β-actin housekeeping gene and the 227 
relative gene expression ratio of each gene was calculated by the cycle threshold (ΔΔCT) 228 
method according to the manufacturer's recommendations. We used an arbitrary cut-off of >1.5-229 
fold change and ≤0.5-fold change for upregulated and downregulated genes, respectively 230 
following the recommendation of QIAGEN "RT2 Profiler PCR Array Data Analysis v3.5 231 
Handbook". Because fold change and statistical cut-offs can modulate the outcome of gene 232 
expression analysis (Dalman et al., 2012), we used less stringent cut-off values to avoid 233 
exclusion of genes that might have a biological relevance. Differential gene expression between 234 
infected and control samples was determined using an unpaired t-test with unequal variance 235 
and P-values of <0.05 were considered significant. 236 
 237 
2.8. Statistical analysis 238 
 239 
Statistical analysis of ELISA measurements was performed in GraphPad Prism version 6. 240 
One-way analysis of variance (ANOVA) followed by Tukey's multiple-comparison test was 241 
used to evaluate differences between groups. Two-way ANOVA followed by Bonferroni 242 
posttests was used to evaluate differences between the groups during the time course of 243 
infection. P values of < 0.05 (*), < 0.01 (**) and < 0.001 (***) were considered statistically 244 
significant.  245 
 246 
3.   Results 247 
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 248 
3.1. Confirmation of F. gigantica infection 249 
 250 
At 70 dpi, livers collected from infected animals showed clear gross pathological lesions 251 
along with the presence of adult F. gigantica flukes, confirming the establishment of a 252 
successful infection in experimentally infected buffaloes. By contrast, livers of the control, 253 
uninfected, buffaloes appeared normal, without any pathological changes and were free of any 254 
F. gigantica flukes. Serological testing using ELISA confirmed the infection in the infected 255 
animals at 28 and 70 dpi. 256 
 257 
3.2. Levels of serum cytokines 258 
 259 
At 3 dpi, the levels of all cytokines, TNF-α, TGF-β, IFN-γ, IL-1B, IL-2, IL-4, IL-5, IL-6, 260 
IL-12, IL-13, IL-17, and IL-18, were significantly reduced in infected buffaloes, probably due 261 
to abnormally high levels of cytokines in control animals (Fig. 1). At 10 dpi, levels of all 262 
cytokines in infected buffaloes were comparable to the levels in control animals, except for IL-263 
5 and IL-17, which was significantly reduced in infected buffaloes compared to controls. 264 
Interestingly, the levels of TGF-β, IL-4 and IL-17 were significantly increased in infected 265 
buffaloes compared to controls at 28 dpi. During the late stage of infection, 70 dpi, differences 266 
in the cytokines between infected and control buffaloes were not statistically significant (P > 267 
0.05). 268 
 269 
3.3. Expression of TLRs and NLRs genes  270 
 271 
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Expression analysis was successfully achieved for all 42 genes in PBMC samples and for 272 
35 genes in liver samples. Our analysis identified many biologically relevant differentially 273 
expressed genes between infected and control animals (Tables S2 and S3). At 3 dpi, gene 274 
expression analysis showed that TIR-domain-containing adapter-inducing interferon-β (TRIF, 275 
also named as TICAM1) was upregulated in the liver and PBMCs of infected buffaloes 276 
compared to controls, whereas TLR4 and TLR8 showed high expression in PBMCs only (Fig. 277 
2). TLR1, TLR5, TLR6, TLR7, TLR9, TLR10, Interferon regulatory factor (IRF) 3, IRF7, NF-278 
κB1, TANK-binding kinase (TBK) 1, NLRP1, CASP1, CD40, CD80, CD86, IFNB1, IL-17A, 279 
IL-2, IL-8, TNF, nucleotide-binding and oligomerization domain containing 1 (NOD1), IFNA1, 280 
and PYCARD were downregulated in the liver, whereas TLR5 and IFNB1 were downregulated 281 
in PBMCs (Fig. 2). The genes whose expression was between 0.5 and 1.5 were deemed non-282 
differentially expressed.  283 
At 10 dpi, TLR1, TLR2, TLR6, TLR10, TRAF6, IRF3, NF-κB1, TBK1, CASP1, CD80, 284 
and IFNA1 were upregulated in infected liver compared to control. In PBMCs, TLR4, TLR9, 285 
TICAM1, NF-κB1, NLRP3, CD86, IL-1B, IL-6, and IL-8 were more expressed in infected 286 
group compared to control (Fig. 3), whereas TLR3 and TLR8 were down-regulated in infected 287 
compared to control. The rest of genes with expression between 0.5 and 1.5 were deemed non-288 
differentially expressed. 289 
At 28 dpi, the levels of TLR3, TLR5, TLR8, TLR9, TLR10, TICAM1, TRAF3, IRF3, IRF7, 290 
NF-κB1, TBK1, NLRP1, NLRP3, CD40, IFNB1, IL-17A, IL-2, IL-8, TNF, NOD1, IFNA1, 291 
and PYCARD were upregulated in the liver of infected animals compared to controls. In 292 
PBMCs, expression of IRF7, IL-18 and IL-12A did not show any differences between infected 293 
and control samples, however the rest of the genes were slightly over expressed in infected 294 
relative to control samples (Fig. 4). 295 
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At 70 dpi, TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, MyD88, 296 
TICAM1, TRAF3, IRF7, NOD2, NLRP1, NLRP3, CASP1, CD40, CD86, IFNB1, IL-17A, IL-297 
18, IL-2, IL-8, TNF, NOD1, IFNA1, and PYCARD were upregulated, and TBK1 and CD80 298 
were downregulated in the liver of infected buffaloes compared to controls (Fig. 5). In PBMCs, 299 
the levels of expression of all genes except IL-18 were downregulated. 300 
 301 
4.   Discussion 302 
 303 
At present, the mechanisms by which F. gigantica engages with the innate immune system 304 
and establish an infection have not yet been precisely elucidated. In the present study, we 305 
examined the levels of cytokines in the serum of experimentally infected buffaloes at 3, 10, 28 306 
and 70 dpi. Diminished host immune cytokines observed at 3 dpi is probably a mechanism 307 
utilized by F. gigantica to facilitate host colonization. While it could be argued that this 308 
apparent reduction in cytokines could be attributed to abnormally high level of cytokines in 309 
control animals, this state of cytokine reduction at early stage of F. gigantica infection has been 310 
observed in previous reports (Girones et al., 2007; Rodriguez et al., 2015; Zhang et al., 2017a). 311 
Also, abnormally high level of cytokines was limited to control animals at 3 dpi, which indicates 312 
that this might have been caused by another underpinning condition/infection specific to this 313 
group. In an effort to counter the infection, the host seems to restore the immunological balance, 314 
which was evident at 10 dpi. By 28 dpi, there was a significant increase in the level of three 315 
cytokines (TGF-β, IL-4 and IL-17) in infected buffaloes, suggesting activation of 316 
Th1/Th2/Th17 immune response. The inflammatory cascades triggered by F. gigantica must 317 
be tightly coordinated in order to avoid severe pathology. Therefore, this coordinated response 318 
is perhaps mediated by the parasite and/or the host to promote the parasite survival, while 319 
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minimizing host tissue damage. By 70 dpi a state of immune homeostasis was observed, which 320 
is probably needed for parasite persistence.  321 
Next, we analyzed alterations in the expression of genes involved in the recognition of and 322 
host defense against F. gigantica infection using custom RT2 Profiler PCR Array. TLRs and 323 
NLRs function as sensors for innate immune response. They detect various pathogen-associated 324 
molecular patterns (PAMPs), followed by activation of signal transduction cascades via 325 
recruiting and interacting with adaptors and other molecules in order to thwart damage induced 326 
by the infecting pathogen (Medzhitov, 2001). There are several adaptor molecules for TLR 327 
signaling, such as MyD88, TRIF, TRIF-related adaptor molecule (TRAM), TIRAP, and TRAF6 328 
whose expression is controlled at the transcriptional level. MyD88 and TICAM1 are the major 329 
adaptors that bind to the intracellular domain of TLR, leading to the induction of the 330 
proinflammatory response via the activation of NF-κB. TLR signaling can also lead to IRF-331 
dependent induction of type I interferons.  332 
At 3 dpi, we detected an increase in the expression of TICAM1 gene in the liver and 333 
upregulation of TICAM1, TLR4 and TLR8 genes in PBMCs. Alteration in the expression of 334 
TLR4 has been detected in F. hepatica infection (Martin et al., 2015; Noya et al., 2017). 335 
TICAM1 gene encodes an adaptor protein possessing a Toll/interleukin-1 receptor (TIR) 336 
homology domain, which interacts with TLR3 and mediates the induction of IFN-β through the 337 
activation of NF-κB (Hardy et al., 2004). TLR4 (CD284) participates in signal transduction 338 
events induced by lipopolysaccharide (LPS) of gram-negative bacteria (Neyen and Lemaitre, 339 
2016). Bacterial lipid A, a component of LPS molecule is specifically recognized by TLR4 and 340 
TLR2 of various host cells, leading to the production of TNF-α, various interleukins, oxygen 341 
radicals, and bioactive lipids (Alexander et al., 2010; Janeway and Medzhitov, 2002).  342 
A structural similarity has been detected between glycolipid AL-II of F. hepatica and the 343 
bacterial lipid A, which has been suggested to be the reason for the similar biological activity 344 
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of both molecules in terms of recognition by TLR4 and TLR2 (Wuhrer et al., 2003). Therefore, 345 
it is reasonable to hypothesize that F. gigantica-specific PAMP is recognized by TLR4, as 346 
indicated by the activation of TLR4 and the adaptor TICAM1. In turn, this activates 347 
transcription factors, such as NF-κB and IRF3, leading to expression of cytokines, such as TNF-348 
α, IL-1β, IL-6, IL-10, and IFN-γ (Palsson-McDermott and O'Neill, 2004). IL-6 cytokine plays 349 
a role in the inflammatory response and maturation of B cells (Hunter and Jones, 2015). It is 350 
unclear why there was no correlation between TLR4 and TICAM1 expression levels and level 351 
of cytokine release. It is possible that, F. gigantica induces upregulation of TLR4, but in the 352 
interim, diminishes buffalo's responsiveness to TLR4 activation by downregulating 353 
lipopolysaccharide binding protein (LBP), as previously reported (Zhang et al., 2017b). At this 354 
point, we cannot conclude whether TICAM via activation of NF-κB or some other mechanisms 355 
is involved in the cytokine production. A future goal of this work will be to examine this 356 
question by determining if NF-κB-dependent regulation of cytokine production is altered when 357 
the TICAM expression is induced. The increased expression of TLR8 (CD288) in PBMCs was 358 
anticipated because TLR8 gene is dominantly expressed in peripheral blood leukocytes. 359 
At 10 dpi, expression analysis revealed upregulation of four TLRs, (TLR1, TLR2, TLR6, 360 
and TLR10) in the liver of infected buffaloes. TLR1 (CD281) gene is ubiquitously expressed 361 
and at higher levels than other TLR genes. TLR2 (CD282) gene promotes apoptosis in response 362 
to bacterial lipoproteins (Quillard et al., 2015). TLR6 (CD286) interacts with TLR2 to mediate 363 
cellular response to bacterial lipoproteins (Noreen and Arshad, 2015). TLR10 (CD209) is 364 
highly expressed in lymphoid tissues (Chuang and Ulevitch, 2001). The activation of these four 365 
TLRs, by as yet unknown F. gigantica-specific PAMPs, must have caused up-regulation of 366 
signaling pathways to modulate the host's inflammatory response.  367 
The subsequent downstream signaling events that follow the activation of these TLRs 368 
included the induction of Interferon Regulatory Factor (IRF) signaling as indicated by increased 369 
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expression of IRF3, interferon alpha 1 (IFNA1), and CD80. IRF3 gene encodes a protein of the 370 
IRF family and forms a complex with CREBBP (Zhao et al., 2016). This complex translocates 371 
to the nucleus and triggers the transcription of interferons alpha and beta, as well as other 372 
interferon-induced genes (Honda et al., 2006). The activated CD80 gene, encodes protein that 373 
induces T-cell proliferation and cytokine production indicating the engagement of adaptive 374 
immunity (Peach et al., 1995). As a member of the TNF receptor associated factor (TRAF) 375 
protein family, TRAF6 mediates signaling from members of the Toll/IL-1 family (e.g. CD40) 376 
and the TNF receptor superfamily (Walsh et al., 2015). Also, it plays significant roles as a signal 377 
transducer in NF-κB pathway which activates IkappaB kinase (IKK) in response to 378 
proinflammatory cytokines and interacts with transforming growth factor (TGF) beta receptor 379 
complex (Walsh et al., 2015). Also, the transcription regulator, NF-κB1, was upregulated, 380 
probably in response to cytokines, TRAF6 activation, oxidant-free radicals or parasite products. 381 
Once triggered NF-κB1 translocates into the nucleus and induces the expression of genes 382 
participating in a wide range of biological functions (Balan and Locke, 2011). TBK1 (TANK 383 
binding kinase) has IKB kinase-like activity (i.e. phosphorylates serine residues on the IKB 384 
proteins, marking them for destruction via the ubiquitination pathway). IKB proteins are known 385 
to inactivate NF-κB by trapping it in the cytoplasm. IRF3 and TBK1 play a key role in 386 
triggering IFN response via activation of IFN-β (Liu et al., 2015). IFN-α exerts a pro-387 
inflammatory function, which contributes to immune-mediated liver damage (Leifeld et al., 388 
2001). CASP1 (Caspase1) is a member of the NF-κB signaling pathway and is known to be 389 
involved in the programmed cell death (Winkler and Rosen-Wolff, 2015).  390 
At 10 dpi, inflammatory response was evident in PBMCs as indicated by increased 391 
expression of CD86, NLRP3, NF-κB1, TICAM1, TLR4, TLR9, IL-1β, IL-6, IL-8. CD86 392 
molecule is expressed by antigen-presenting cells and acts as a ligand for CD28 antigen for 393 
activation of T-cell and binds with cytotoxic T-lymphocyte-associated protein 4 to suppress T-394 
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cell activation (Gu et al., 2012). NOD-like receptor (NLR)P3 inflammasome plays a role in the 395 
regulation of inflammation, immune response, and apoptosis, and is linked to NF-κB signaling 396 
(Boaru et al., 2015). TICAM1 induces IFN-β through activation of NF-κB. Increased 397 
expression of TLR4 (CD284) has been implicated in signal transduction events induced by LPS. 398 
Also, TLR9 (CD289) was upregulated and was predominantly expressed in PBMCs. IL-1β is a 399 
major mediator of the inflammatory response, and participates in a range of cellular activities, 400 
including cell proliferation, differentiation, and apoptosis (Netea et al., 2015). IL-6 cytokine 401 
plays a role in the inflammatory response and maturation of B cells (Hunter and Jones, 2015). 402 
IL-8, secreted by several cell types, mediates the inflammatory response, and functions as a 403 
chemoattractant and a potent angiogenic factor (Singh et al., 2013). 404 
At 28 dpi, the majority of the examined genes were upregulated especially TLR3, TLR10, 405 
TRAF3, TICAM1, IFNA1, NLRP1, and NLRP3 in the liver and IL-10 in PBMCs. 406 
TRAF3, TNF receptor associated factor 3, functions in lymphotoxin-beta receptor signaling 407 
complex, which induces NF-κB activation and cell death (Hu et al., 2016). Interestingly, NF-408 
κB activation induced the expression of the inflammasomes NLRP1 and NLRP3 (and their 409 
adaptor protein PYCARD), leading to activation of caspase-1 and subsequent processing of 410 
bioactive IL-1β (Srinivasula et al., 2002).  411 
At 70 dpi, there was an increase in the expression of NLRP1 and NLRP3 inflammasomes, 412 
which induce caspase-1-dependent maturation of IL-1β (Fernandes-Alnemri et al., 2009; Halle 413 
et al., 2008). The activation of nucleotide-binding oligomerization domain 2 (NOD2) protein, 414 
which senses pathogens, may contribute to host defense via the production of pro-inflammatory 415 
cytokines (Keestra-Gounder et al., 2016). The activation of the inflammasome in parasitic 416 
diseases, such as malaria, leishmaniosis, trypanosomiasis, amoebiasis, naegleriasis, and 417 
toxoplasmosis, has been investigated (Zamboni and Lima-Junior, 2015). To our knowledge, 418 
this is the first documentation of the involvement of inflammasomes in F. gigantica infection 419 
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in buffaloes. We also detected activation of TLR7-and TLR9 genes, which along with increased 420 
gene expression of the surface marker CD40 can provide co-stimulatory signals for increased 421 
proliferation and activation of B cells, which is critical for the promotion of Th2 immune 422 
response. This pattern of Th1/Th2 immune response associated with late infection reflects the 423 
concomitant upregulation of the pro- and anti-inflammatory cytokines, B cells activation and 424 
the levels of pro- and anti-inflammatory gene expression.  425 
In conclusion, the study resulted in several important findings. First, early infection 426 
induced modest activation of TLR4 and TLR8 and TICAM1. Second, at 10 dpi, NF-κB 427 
(TRAF6, NFKB1, TBK1, CASP1) and Interferon Regulatory Factor (IRF; IRF3, IFNA1, 428 
CD80) signaling pathways were upregulated in response to activation of TLR1, TLR2, TLR6, 429 
and TLR10 in the liver, and inflammatory response (IL-8, CD86, NLRP3, NFKB1, TICAM-1) 430 
and activated TLR4 and 9 in PBMCs. However, it is not yet possible to be sure that higher gene 431 
expression equates to increased cytokine production. Third, at 28 dpi, marked enhancement in 432 
the immune response was detected in both liver and PBMC samples, including inflammasome-433 
dependent innate immune responses mediated by NLRP1 and NLRP3. Enhancement of the 434 
immune response correlated with increased levels of cytokines. Fourth, at 70 dpi, F. gigantica 435 
induced a local immune response in hepatic tissue mediated by TLRs and NLRs and their 436 
downstream interacting and adaptor molecules, which correlated with a systemic Th1/Th2 437 
immune response. These data uncovered new immune signaling cascades and expression 438 
patterns of TLRs and NLRs during F. gigantica infection and should be important for 439 
understanding the interaction of F. gigantica with the innate immune system of buffaloes. 440 
Further investigation of how F. gigantica infection and these innate PRRs’ signaling pathways 441 
intersect may provide new insights into the roles of the pathways involved, their constituent 442 
proteins, which ultimately may reveal new functions of these innate immunity pathways that 443 
could be manipulated therapeutically. 444 
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Figure Legends 632 
 633 
Fig. 1. The effect of Fasciola gigantica on the levels of the 12 indicated cytokines in the serum 634 
of experimentally infected buffaloes. Red and green bars represent infected and control groups, 635 
respectively. Data are expressed as means ± SD from three different animals (*, P < 0.05; **, 636 
P < 0.01; ***, P < 0.001, compared with control, uninfected animals). 637 
 638 
Fig. 2. Results of the qRT-PCR analysis showing the levels of expression of immunity-related 639 
genes in the liver (A) and peripheral blood mononuclear cells (B) of buffaloes infected with 640 
Fasciola gigantica at 3 dpi. Red and green colors represent upregulated (fold change > 1.5) and 641 
downregulated (fold change ≤ 0.5) genes between infected and uninfected buffaloes, 642 
respectively. Black bars represent genes whose expression was between 0.5 and 1.5 and were 643 
considered non-differentially expressed. Expression levels were normalized against the 644 
reference housekeeping gene β-actin. 645 
 646 
Fig. 3. qRT-PCR results showing the levels of expression of immunity-related genes in the liver 647 
(A) and peripheral blood mononuclear cells (B) of buffaloes infected with Fasciola gigantica 648 
compared to uninfected buffaloes at 10 dpi. Red, up-regulation; green, down-regulation; black, 649 
no change. Fold changes were computed for Ct values of amplified mRNA in comparison to 650 
those of housekeeping gene β-actin. 651 
 652 
Fig. 4. qRT-PCR results showing the levels of expression of immunity-related genes in the liver 653 
(A) and peripheral blood mononuclear cells (B) of buffaloes infected with Fasciola gigantica 654 
compared to uninfected buffaloes at 28 dpi. Red, up-regulation; green, down-regulation; black, 655 
no change. Fold changes were computed for Ct values of amplified mRNA in comparison to 656 
those of housekeeping gene β-actin. 657 
28 
 
 658 
Fig. 5. qRT-PCR results showing the levels of expression of immunity-related genes in the liver 659 
(A) and peripheral blood mononuclear cells (B) of buffaloes infected with Fasciola gigantica 660 
compared to uninfected buffaloes at 70 dpi. Red, up-regulation; green, down-regulation; black, 661 
no change. Fold changes were computed for Ct values of amplified mRNA in comparison to 662 
those of housekeeping gene β-actin. 663 





Table S1 
List of the 42 TLR and NLR-related genes whose expression profiles were investigated 
in the present study. 
 
Gene 
Symbol * 
Full Name of gene target 
TLR1 Toll-like receptor 1 
TLR2 Toll-like receptor 2 
TLR3 Toll-like receptor 3 
TLR4 Toll-like receptor 4 
TLR5 Toll-like receptor 5 
TLR6 Toll-like receptor 6 
TLR7 Toll-like receptor 7 
TLR8 Toll-like receptor 8 
TLR9 Toll-like receptor 9 
TLR10 Toll-like receptor 10 
MYD88 Myeloid differentiation primary response gene (88) 
TICAM1 Toll-like receptor adaptor molecule 1 
TRAF3 TNF receptor-associated factor 3 
TRAF6 TNF receptor-associated factor 6 
IRF3 Interferon regulatory factor 3 
IRF7 Interferon regulatory factor 7 
NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 
TBK1 TANK-binding kinase 1 
NOD2 Nucleotide-binding oligomerization domain containing 2 
RIPK2 Receptor-interacting serine-threonine kinase 2 
NLRP1 NLR family, pyrin domain containing 1 
NLRP3 NLR family, pyrin domain containing 3 
CASP1 Caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, 
convertase) 
CD40 CD40 molecule, TNF receptor superfamily member 5 
CD80 CD80 molecule 
CD86 CD86 molecule 
IFNB1 Interferon, beta 1, fibroblast 
IFNG Interferon, gamma 
IL10 Interleukin 10 
IL13 Interleukin 13 
IL17A Interleukin 17A 
IL18 Interleukin 18 (interferon-gamma-inducing factor) 
IL1B Interleukin 1, beta 
IL2 Interleukin 2 
* Expression levels of the above listed 42 genes were normalized against beta actin 
(ACTB) as the reference housekeeping gene. 
IL4 Interleukin 4 
IL6 Interleukin 6 (interferon, beta 2) 
IL8 Interleukin 8 
IL12A Interleukin 12A (natural killer cell stimulatory factor 1, cytotoxic 
lymphocyte maturation factor 1, p35) 
TNF Tumor necrosis factor 
NOD1 Nucleotide-binding oligomerization domain containing 1 
IFNA1 Interferon, alpha, leukocyte 
PYCARD PYD and CARD domain containing 
Table S2. Quantitative real time PCR expression data for immunity-related genes in the liver of buffaloes infected with Fasciola gigantica. 
 
Gene 
Symbol Full Name of the Gene 
3 DPI 10 DPI 28 DPI 70 DPI 
Control Infected Control Infected Control Infected Control Infected 
TLR1 Toll-like receptor 1 5.81±3.54 7.42±3.97 8.22±0.96 7.87±0.31 8.17±1.59 7.94±1.85 8.67±0.96 5.79±0.61* 
TLR2 Toll-like receptor 2 5.51±3.26 4.46±6.05 7.84±1.08 7.55±0.49 7.55±0.86 7.49±1.62 6.16±1.9 5.79±0.61 
TLR3 Toll-like receptor 3 4.9±6.08 6.29±3.33 7.47±0.4 7.89±0.7 8.26±1.37 7.11±1.19 7.95±0.11 5.79±0.61* 
TLR4 Toll-like receptor 4 5.85±2.6 6.05±3.29 7.15±1.6 7.1±0.4 8±1.22 7.2±1.59 7.3±1.04 5.79±0.61 
TLR5 Toll-like receptor 5 7.25±3.96 6.33±6.61 8.59±1.22 8.99±1.02 7.76±1.23 7.71±1.71 6.22±1.67 5.79±0.61 
TLR6 Toll-like receptor 6 6.28±3.14 7.26±3.83 7.85±1.09 6.92±0.23 7.97±1.13 7.52±1.59 7.4±0.89 5.79±0.61 
TLR7 Toll-like receptor 7 4.46±8.57 3±12.34 8.56±1.19 8.56±1.56 7.77±1.23 7.32±1.62 8.71±1.03 5.79±0.61* 
TLR8 Toll-like receptor 8 0.9±10.62 5.58±4.11 7.85±1 7.82±0.37 8.16±1.38 6.86±0.98 6.88±1.89 5.79±0.61 
TLR9 Toll-like receptor 9 7.25±3.96 7.46±4.69 8.59±1.22 8.93±1.09 7.93±1.21 7.98±1.88 8.71±1.03 5.54±0.56* 
TLR10 Toll-like receptor 10 5.41±3.53 6.52±3.29 7.77±1.14 7.47±0.87 8.55±1.7 6.71±0.79 5.29±4.14 5.76±0.58 
MYD88 Myeloid differentiation primary response gene (88) 5.85±2.69 5.42±5.73 7.86±1.08 8.14±0.59 7.88±1.21 7.98±1.88 6.89±1.2 5.79±0.61 
TICAM1 Toll-like receptor adaptor molecule 1 6.22±5.67 6.79±4.39 8.59±1.22 8.06±1.71 8.1±1.27 6.77±1.05 8.34±1.44 5.79±0.61* 
TRAF3 TNF receptor-associated factor 3 7.18±3.97 6.48±5.18 8.22±0.96 8.01±0.95 8.23±1.35 7.27±1.34 8.55±1.08 5.79±0.61* 
TRAF6 TNF receptor-associated factor 6 4.84±1.84 1.82±7.86 5.52±0.61 4.86±0.19 5.81±0.32 5.69±0.3 4.97±0.38 5.42±0.59 
IRF3 Interferon regulatory factor 3 3.39±3.22 4.91±2.05 4.49±0.46 3.13±1.23 4.86±1.21 3.95±0.84 3.28±1.41 4.7±1.48 
IRF7 Interferon regulatory factor 7 7.25±3.96 6.66±6.06 8.59±1.22 8.32±0.92 8.62±1.76 7.24±1.64 6.94±1.39 5.79±0.61 
NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 2.32±4.65 3.26±3.91 4.51±0.5 3.89±0.28 4.62±0.66 3.78±0.69 3.76±0.67 4.18±1.71 
TBK1 TANK-binding kinase 1 0.8±4.5 3.86±0.95 3.13±0.78 2.36±0.55 4.17±0.74 3.39±1.06 2.19±0.32 5.32±0.7* 
NOD2 Nucleotide-binding oligomerization domain containing 2 6.74±3.34 6.47±5.41 8.55±1.18 8.57±0.4 7.52±1.37 7.94±1.86 8.71±1.03 5.79±0.61* 
RIPK2 Receptor-interacting serine-threonine kinase 2 4.51±1.4 4.59±1.53 5.08±1.65 5.28±0.27 5.44±0.8 5.57±0.49 5.11±1.2 5.79±0.61 
NLRP1 NLR family, pyrin domain containing 1 5.26±7.06 7.5±4.06 8.45±1.33 8.19±0.73 8.23±1.35 7.18±1.2 8.64±1 5.79±0.61* 
NLRP3 NLR family, pyrin domain containing 3 6.88±3.49 7.66±4.27 8.22±0.96 8.7±0.58 8.22±1.34 7.69±1.68 7.71±1.31 5.79±0.61 
CASP1 Caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase) 5.84±2.88 7.12±3.7 8±1.11 7.24±0.68 8.02±1.2 7.49±1.57 7.07±1.71 5.79±0.61 
CD40 CD40 molecule, TNF receptor superfamily member 5 6.81±3.41 7.57±4.4 8.31±1.14 8.58±0.45 8.04±1.24 7.6±1.65 8.71±1.03 5.79±0.61* 
CD80 CD80 molecule 5.46±4.97 7.26±4.01 7.94±0.94 6.84±0.75 7.97±1.18 7.23±1.24 1.63±1.06 5.79±0.61 
CD86 CD86 molecule 5.05±3.53 6.08±3.86 7.72±1.13 8.02±0.41 7.93±1.17 6.95±1.07 6.84±1.07 5.79±0.61 
IFNB1 Interferon, beta 1, fibroblast 7.25±3.96 7.5±4.63 8.59±1.22 8.99±1.02 8.62±1.76 7.98±1.88 8.71±1.03 5.79±0.61* 
IL17A Interleukin 17A 6.85±4.62 7.7±4.29 8.59±1.22 8.99±1.02 8.62±1.76 7.98±1.88 8.71±1.03 5.79±0.61* 
IL18 Interleukin 18 (interferon-gamma-inducing factor) 3.69±1.64 3.56±3.27 4.62±0.65 5.08±0.53 6.06±1.3 6.19±0.66 6.14±0.23 5.35±0.55 
IL2 Interleukin 2 7.25±3.96 6.98±5.51 8.59±1.22 8.99±1.02 8.62±1.76 7.94±1.86 8.71±1.03 5.79±0.61* 
IL8 Interleukin 8 4.55±8.51 7.7±4.29 8.59±1.22 8.99±1.02 8.62±1.76 7.98±1.88 8.71±1.03 5.79±0.61* 
TNF Tumor necrosis factor 4.42±5.4 6.66±6.04 8.59±1.22 8.99±1.02 8.62±1.76 7.98±1.88 8.71±1.03 5.79±0.61* 
NOD1 Nucleotide-binding oligomerization domain containing 1 5.74±2.56 6.31±3.84 7.94±0.73 8.62±0.47 8.26±1.38 7.9±1.82 7.47±0.57 5.79±0.61 
IFNA1 Interferon, alpha, leukocyte 3.96±4.1 5.47±4.15 6.21±0.68 5.37±0.55 6.8±0.22 5.32±0.59 5.28±0.44 5.16±0.73 
PYCARD PYD and CARD domain containing 6.88±4.56 5.52±8 8.59±1.22 8.83±1.24 8.62±1.76 7.98±1.88 8.71±1.03 5.79±0.61* 
 
* P<0.05 vs control. Data are the average ΔCt ± SD. n = 3 buffaloes per group.	  Expression levels were normalized against the reference housekeeping gene β-actin. 
 
 
 
 
 
 
 
 
 
 
Table S3. Quantitative real time PCR expression data for immunity-related genes in the peripheral blood mononuclear cells of buffaloes infected with Fasciola gigantica. 
 
Gene 
Symbol Full Name of the Gene 
3 DPI 10 DPI 28 DPI 70 DPI 
Control Infected Control Infected Control Infected Control Infected 
TLR1 Toll-like receptor 1 3.78±3.68 4.08±2.6 5.88±3.45 6.32±1.63 6.76±0.23 4.19±5.37 3.76±3.06 6.74±1.82 
TLR2 Toll-like receptor 2 3.55±3.03 3.41±1.45 5.54±3.1 5.01±1.51 7.38±0.65 4.5±4.95 3.57±2.75 6.25±0.32 
TLR3 Toll-like receptor 3 4.5±3.98 4.81±3.68 6.47±4.19 7.34±2.71 7.94±0.14 4.48±4.89 3.96±3.47 7.84±2.48 
TLR4 Toll-like receptor 4 3.06±2.47 2.46±0.47 4.81±2.82 3.97±1.2 6.07±0.46 3.58±3.64 3.01±1.74 6.25±0.74 
TLR5 Toll-like receptor 5 4.94±3.9 6.56±2.44 6.77±4.76 7.6±2.44 7.94±0.14 4.13±1.94 4.75±2.78 9.54±3.69 
TLR6 Toll-like receptor 6 4.64±3.68 4.63±2.99 6.13±3.61 6.57±2.42 6.62±0.43 4.49±4.95 3.92±3.41 7.13±2.22 
TLR7 Toll-like receptor 7 5.49±3.13 5.32±2.96 7.22±3.82 7.79±2.2 7.89±0.2 5.41±4.9 4.97±2.63 8.37±2.73 
TLR8 Toll-like receptor 8 5.04±3.51 4.6±3.03 6.56±4.25 7.42±2.59 7.66±0.25 4.63±5.15 4.66±3.03 8.33±1.76 
TLR9 Toll-like receptor 9 5.45±3.17 5.79±3.02 7.24±2.9 7.01±1.66 7.94±0.14 5.5±5.09 5.19±2.33 7.8±1.85 
TLR10 Toll-like receptor 10 4.63±3.89 4.9±3.44 6.28±3.93 6.76±2.59 6.7±0.09 4.49±4.95 4±3.43 6.99±2.33 
MYD88 Myeloid differentiation primary response gene (88) 4.72±2.71 4.98±2.25 5.7±2.63 6.05±1.07 6.76±0.04 4.29±3.25 4.25±2.25 7.29±1.19 
TICAM1 Toll-like receptor adaptor molecule 1 7.26±1.62 6.45±2.35 7.87±2.96 7.2±2.58 7.94±0.14 4.99±4.93 6.35±1.48 8.51±1.91 
TRAF3 TNF receptor-associated factor 3 4.7±2.09 4.63±1.48 5.5±2.01 5.06±1.08 6.43±0.72 4.51±3.53 4.29±1.45 6.68±1.64 
TRAF6 TNF receptor-associated factor 6 4.39±3.17 4.26±1.51 5.37±2.97 5.23±1.36 7.22±0.07 4±4.24 3.52±2.06 6.58±1.44 
IRF3 Interferon regulatory factor 3 5.13±3.43 5.17±3.54 6.92±4.43 7.31±2.85 7.89±0.07 5.03±5.6 4.32±3.2 8.61±2.12 
IRF7 Interferon regulatory factor 7 8.16±1.06 8.13±1.49 8.71±1.05 8.56±1.29 7.94±0.14 7.15±2.75 7.33±0.54 8.64±2.13 
NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 3.12±1.64 2.83±0.97 4.03±1.78 3.24±1.42 4.86±0.11 3.34±3.75 2.62±1.07 4.92±1.19 
TBK1 TANK-binding kinase 1 3.19±2.48 3.1±1.74 4.38±2.64 4.24±1.67 5.7±0.33 3.82±4.47 3.28±2.24 5.84±1.58 
NOD2 Nucleotide-binding oligomerization domain containing 2 4.57±3.89 4.62±2.99 6.57±4.03 7.01±2.28 6.96±0.03 4.94±5.73 4.1±3.35 7.99±1.96 
RIPK2 Receptor-interacting serine-threonine kinase 2 3.72±2.06 3.85±1.85 4.87±2.51 4.47±0.96 6.04±0.43 3.49±3.53 2.96±1.65 6.04±1.28 
NLRP1 NLR family, pyrin domain containing 1 4.62±3.55 4.64±3.03 6.71±4.19 6.99±2.93 7.42±0.87 4.49±4.95 4.21±3.27 8.31±2.51 
NLRP3 NLR family, pyrin domain containing 3 3.69±2.74 3.35±1.45 6.02±3.54 4.22±1.57 7.5±0.49 4.02±4.27 3.39±2.14 7.03±0.38 
CASP1 Caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase) 4.46±3.16 4.54±1.75 6.4±3.33 5.82±1.17 7.18±0.61 5.24±4.59 4.62±2.82 7.57±1.45 
CD40 CD40 molecule, TNF receptor superfamily member 5 3.96±2.66 3.87±1.81 5.21±2.89 5.02±1.09 5.09±0.67 3.99±4.25 3.47±2.55 5.75±1.84 
CD80 CD80 molecule 4.44±3.14 4.78±1.93 4.97±2.71 5.22±1.33 5.84±0.15 4.68±4.62 3.91±1.69 6.64±2 
CD86 CD86 molecule 4.06±2.6 4.04±1.82 6.08±3.55 5.23±1.37 6.85±0.2 4.5±4.95 3.6±2.08 6.42±1.34 
IFNB1 Interferon, beta 1, fibroblast 7.19±3.52 9.58±1.01 7.7±3.23 8.34±1.68 7.56±0.66 5.6±4.94 6.69±0.88 9.54±3.69 
IFNG Interferon, gamma 4.06±3.92 4.57±3.01 6.67±4.67 7.05±3.07 7.76±0.12 4.91±5.55 3.98±3.45 8.32±2.58 
IL10 Interleukin 10 4.99±3.58 6.51±3.69 5.99±3.08 5.64±1.31 7.94±0.14 -0.33±3.83 5.28±2.23 7.76±0.67 
IL13 Interleukin 13 4.63±3.77 4.64±3 6.9±4.54 7.09±3.13 7.89±0.07 3.93±4.54 4±3.44 8.11±2.24 
IL17A Interleukin 17A 4.61±3.91 4.96±3.54 6.91±4.43 7.28±2.89 7.94±0.14 4.43±5.03 4.29±3.21 8.7±2.33 
IL18 Interleukin 18 (interferon-gamma-inducing factor) 9.51±0.52 9.41±0.92 9.1±1.43 8.74±1.58 7.94±0.14 8.6±0.7 8.43±0.59 8.5±1.9 
IL1B Interleukin 1, beta 1.22±1.19 0.84±1.06 4.09±2.03 1.04±1.08 7.9±0.08 2.37±2.08 -0.24±2.34 5.14±3 
IL2 Interleukin 2 4.81±3.77 5.2±3.57 6.91±4.45 7.22±2.97 7.94±0.14 5.18±5.53 4.11±3.34 8.75±2.4 
IL4 Interleukin 4 5.01±3.56 5.34±3.42 6.95±4.46 7.45±2.65 7.94±0.14 5.16±5.57 4.43±3.07 9.12±3.11 
IL6 Interleukin 6 (interferon, beta 2) 4.27±3.06 3.85±1.6 6.95±4.46 5.52±1.83 7.9±0.08 5.18±5.54 3.78±2.29 7.5±0.35 
IL8 Interleukin 8 6.72±1.61 6.32±0.61 7.58±2.42 6.95±1.11 7.94±0.14 6.54±2.33 4.52±1.69 7.65±0.51 
IL12A 
Interleukin 12A (natural killer cell stimulatory factor 1, cytotoxic lymphocyte maturation factor 
1, p35) 8.79±0.8 8.48±1.25 8.72±1.73 8.82±1.6 7.94±0.14 7.66±2.02 7.36±1.11 9.49±3.6 
TNF Tumor necrosis factor 6.17±2.08 6.31±1.47 7.95±2.83 8.43±1.56 7.94±0.14 6.17±3.03 5.49±1.31 8.38±1.69 
NOD1 Nucleotide-binding oligomerization domain containing 1 6.28±2.48 6.85±2.25 7.67±3.28 8.56±1.59 7.94±0.14 5.88±3.52 5.92±1.77 8.51±1.91 
IFNA1 Interferon, alpha, leukocyte 4.5±3.93 4.32±2.42 6.71±4.19 6.85±2.84 7.51±0.32 4.43±4.86 4.1±3.39 7.45±1.95 
PYCARD PYD and CARD domain containing 4.48±4 5.07±3.57 6.95±4.47 7.3±2.85 7.9±0.08 3.42±3.43 4.38±3.13 8.35±2.89 
 
* Data are the average ΔCt ± SD. n = 3 buffaloes per group.	  Expression levels were normalized against the reference housekeeping gene β-actin. 
